|
4.3角膜溃疡
由于角膜溃疡中各种组织降解酶在病情发展中发挥了重要的作用，如果可以增强角膜组织对抗酶消化作用的能力，无疑可以延缓组织溃疡的发展[2]。受此启发，Moren等[20]对一个由于配戴角膜接触镜引起单眼角膜溃疡的女性进行治疗，实验检查排除单纯疱疹病毒,细菌和棘阿米巴感染，患者最佳矫正视力(BCVA)0.02，开始应用广谱抗生素治疗1mo，角膜继续浸润性溃疡、角膜变薄。考虑患者对常规治疗无效果后，给予患者使用CCL治疗。治疗过程中观察患者的疼痛和坏死物质迅速减少，几天内角膜上皮开始恢复，1mo后上皮完全长好，2mo后溃疡基本恢复，治疗9mo后，BCVA 20/30。这个病例表明CCL对感染性角膜炎的治疗有积极的影响，患者治疗后最终的视觉效果令人满意。尽管这项技术并不成熟，但这可能是一种很有前景的治疗角膜炎的新方法。
5前景与展望
紫外光核黄素角膜交联疗法的出现，为圆锥角膜、医源性角膜扩张、角膜溃疡等疾病的治疗带来了新的希望。尽管实验和临床研究已经初步证实了该疗法的作用机制和疗效，在减轻患者治疗上的不适亦取得了进一步成效，但是作为一个新的治疗手段，紫外光核黄素角膜交联疗法还不够完善，在此基础上不断会有新的疗法产生，并且远期疗效和安全性尚需进一步研究。另外，最近一项研究 表明紫外光核黄素交联作用可以提高巩膜的机械强度，进行性近视发病的重要原因可能是巩膜的生物力学强度下降和变薄[21]，利用紫外光核黄素交联疗法使巩膜纤维发生交联而增强其强度，阻止或延缓近视的病理进程，但同时此手术中需暴露巩膜，对视网膜有细胞毒性作用影响治疗中辐射范围[22]。 此外，利用CCL使角膜基质发生水合作用(交联程度越高，水肿程度越低)，使交联术治疗大疱性角膜病变等病成为了可能[23]，然而这一切都需要我们做进一步研究，完善手术方法，提高疗效及应用范围。
【参考文献】
1 Wollensak G.Crosslinking treatment of progressive keratoconus: new hope. Curr Opin Ophthalmol 2006;17(4):356360
2 Wollensak G ,Sporl E. Treatment of keratoconus by collagen crosslinking. Ophthalmologe 2003;100(1):4449
3 Spoerl E, Mrochen M, Sliney D, et al. Safety of UVAribofl avin crosslinking of the cornea. Cornea 2007;26(4):385389
4潘红卫，陈建苏.紫外光核黄素交联治疗圆锥角膜的研究进展.眼科研究 2008;26(5)：397400
5刘祖国.眼表疾病学.北京：人民卫生出版社 2003：5603
6 Wollensak G，Wilsch M ，Spoefl E， et al. Collagen fiber diameter in the rabbit cornea after collagen crosslinking by riboflavin/UVA. Cornea 2004;23(5)：503507
7 Spoerl E, Wollensak G, Seiler T.Increased resistance of crosslinked cornea against enzymatic digestion. Curr Eye Res 2004;29(1):3540
8 Pinelli R. Update on Corneal Crosslinking. J Cataract Refract Surg 2008;24(5):494500
9 Wollensak G, Spoerl E, Seiler T. Riboflavin/ultravioletainduced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol 2003;135(5):620627
10 Seiler T, Hafezi F. Corneal crosslinkinginduced stromal demarcation line. Cornea 2006;25:10571059
11 McCall AS, Kraft S, Edelhauser HF, et al. Mechanisms of corneal tissue crosslinking in response to treatment with topical riboflavin and longwavelength ultraviolet radiation (UVA). Invest Ophthalmol Vis Sci 2010;51(1):129138
12 Kymionis GD, Diakonis VF, Coskunseven E,et al. Customized pachymetric guided epithelial debridement for corneal collagen cross linking. BMC Ophthalmol 2009;9:10
13 Wollensak G, Spoerl E, Seiler T, et al. Stressstrain measurements of human and porcine corneas after riboflavinultravioletAinduced crosslinking. J Cataract Refract Surg 2003;29(9):17801785
14 Mencucci R, Mazzotta C, Rossi F, et al. Ribofl avin and ultraviolet A collagen crosslinking: in vivo thermographic analysis of the corneal surface. J Cataract Refract Surg 2007;33(6):10051008
15 Raiskup F, Hoyer A, Spoerl E. Permanent corneal haze after riboflavinUVAinduced crosslinking in keratoconus. J Refract Surg 2009;25(9):S824828
16 RaiskupWolf F, Hoyer A, Spoerl E, et al.Collagen crosslinking with riboflavin and ultravioletA light in keratoconus:Longterm results. J Cataract
Refract Surg 2008;34(5):796801
17 Hafwzi F, Kanelloppulos J,Wiltfang R, et al. Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis. J Cataract Refract Surg 2007;33(12):20352040
18 Kohlhaas M, Spoerl E, Speck A, et al. A new treatment of keratectasia after LASIK by using collagen with ribofl avin/UVA light crosslinking. Klin Monatsbl Augenheilkd 2005;222(5):430436
19 Kampik D, Ralla B, Keller S, et al. Influence of corneal collagen crosslinking with riboflavin and ultravioleta irradiation on excimer laser surgery. Invest Ophthalmol Vis Sci 2010;51(8):39293934
20 Moren H, Malmsjo M, Mortensen J, et al. Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis. Cornea 2010;29:102104
21 Awetissow ES. Unterlagen zur entstehungstheorie der myopie. mitteilung die sclera in der pathogenese der progredienten myopie. Klin
Monatsbl Augenheilkd 1980;176:777781
22 Wollensak G, Iomdina E, Dittert DD, et al. Crosslinking of sclera collagen in the rabbit using riboflavin and UVA. Acta Ophthlmol Scand 2005;83:477482
23 Wollensak G,Aurich H,Wirbelauer C. Potential use of riboflavin/UVA crosslinking in bullous keratopathy. Ophthalmic Res 2009;41:114117 上一页 [1] [2] |
